
๐ข ๐๐๐๐ ๐๐: EU Approves Novo Nordisk's Oral Wegovy for Obesity Treatment - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค ๐๐ฎ๐ซ๐จ๐ฉ๐๐๐ง ๐๐จ๐ฆ๐ฆ๐ข๐ฌ๐ฌ๐ข๐จ๐ง approves ๐จ๐ซ๐๐ฅ ๐๐๐ ๐จ๐ฏ๐ฒ ๐๐ ๐ฆ๐ .โค Approval covers adults with ๐จ๐๐๐ฌ๐ข๐ญ๐ฒ or overweight with comorbidities.โค Oral Wegovy becomes Novo Nordisk's ๐๐ข๐๐ญ๐ก regulatory approval globally.โค OASIS 4 trial showed approximately ๐๐% mean weight loss over 64 weeks.โค Placebo group recorded approximately ๐๐% mean weight loss.โค Around ๐จ๐ง๐ ๐ข๐ง ๐ญ๐ก๐ซ๐๐ participants lost ๐๐๐% or more body weight.โค EU also approved ๐๐๐ ๐จ๐ฏ๐ฒ ๐.๐ ๐ฆ๐ single-dose injection pen.โค Novo Nordisk says the injection delivers approximately ๐๐๐% weight loss.โค Company plans additional global launches in ๐ญ๐ก๐ ๐ฌ๐๐๐จ๐ง๐ ๐ก๐๐ฅ๐ ๐จ๐ ๐๐๐๐.๐ ๐๐ฑ๐ฉ๐๐ซ๐ญ ๐๐ญ๐๐ญ๐๐ฆ๐๐ง๐ญ:๐๐ข๐ค๐ ๐๐จ๐ฎ๐ฌ๐ญ๐๐๐ซ, president and CEO of Novo Nordisk:"For many people, a tablet may be a simpler and more acceptable way to start and continue treatment."The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
